In a significant move for the field of dental sleep medicine, SomnoMed Limited—a global leader in the development of oral appliance therapy (OAT)—has officially initiated a controlled market release of its latest innovation, the Virtus device. This new oral appliance is specifically engineered to address a common yet challenging clinical overlap: patients suffering from both mild to moderate obstructive sleep apnea (OSA) and sleep bruxism (teeth grinding).
The rollout, spanning North America, Europe, and the Asia-Pacific region, marks a pivotal moment for clinicians who have long sought a durable, comfortable, and effective solution for patients whose nocturnal grinding often compromises the longevity of standard sleep apnea appliances.
The Clinical Necessity: Addressing the "Double Burden"
For millions of individuals, sleep is not a restorative period of rest but a nightly struggle against two distinct yet often comorbid conditions. Obstructive sleep apnea, characterized by the collapse of the upper airway during sleep, results in fragmented breathing and decreased blood oxygen levels. Simultaneously, sleep bruxism involves the involuntary clenching or grinding of teeth, which can lead to severe dental attrition, jaw pain, and tension headaches.
Historically, patients requiring treatment for OSA were prescribed oral appliances that, while effective at keeping the airway open by advancing the mandible, were not always built to withstand the high-intensity mechanical stress of chronic grinding. The Virtus device aims to bridge this gap. By utilizing advanced materials and structural reinforcements, SomnoMed has designed a device that offers the therapeutic airway benefits of their established technology while providing the ruggedness necessary for bruxers.
Product Engineering and Technical Evolution
At its core, the Virtus device is an evolution of SomnoMed’s highly successful predicate device, the SomnoDent Avant. While the fundamental scientific principles of operation remain consistent—maintaining airway patency through mandibular advancement—the Virtus introduces several material and structural upgrades designed for enhanced durability.
Material Science and Structural Integrity
One of the most immediate visual differences is the use of clear poly(methyl methacrylate) (PMMA). Unlike traditional pigmented versions, the clear PMMA offers an aesthetic, low-profile appearance. More importantly, however, is the mechanical overhaul of the device’s internal components. The Virtus incorporates an updated polyamide strap that now features an internal metal core. This metallic reinforcement provides superior tensile strength, allowing the appliance to endure the repeated, high-force cycles of nocturnal clenching without fracturing or losing its calibrated advancement setting.
Compatibility and Clinical Efficacy
The Virtus has received FDA 510(k) clearance, confirming its safety and efficacy for patients 18 years of age and older diagnosed with mild to moderate obstructive sleep apnea and primary snoring. By maintaining the same “fit and feel” philosophy that has defined SomnoMed’s portfolio, the transition for patients already accustomed to the Avant or similar appliances is expected to be seamless. The modification of fixing elements to accommodate the new, more robust strap geometry ensures that the device remains easy for patients to insert and remove, which is a critical factor in long-term therapy adherence.
Executive Transitions: A New Leadership Era
The product launch coincides with a strategic reshuffling of SomnoMed’s executive leadership, signaling a new chapter for the organization. As of July 27, the company transitioned from a co-CEO model to a single-CEO structure.
The Departure of Amrita Blickstead
Amrita Blickstead, who served as co-CEO and executive director, has stepped down from her position after six years with the company. During her tenure, Blickstead was instrumental in navigating the company through complex periods of change, focusing on the professionalization of the workforce and the development of a high-performance team. Her departure is viewed by the board as a planned evolution in the company’s governance structure.
Karen Borg Assumes Global Leadership
Karen Borg, who had been serving as co-CEO alongside Blickstead since February 2024, has now assumed the sole role of CEO. Borg’s leadership is expected to prioritize global market expansion and the continued integration of clinical innovation into the company’s product pipeline.
"I have thoroughly enjoyed working with Amrita as co-CEO and have valued our partnership leading the SomnoMed team," said Borg in an official press release. "Our daily collaboration was central to the turnaround of the company and has enabled a solid foundation for its future."
Blickstead echoed these sentiments, expressing confidence in the team she leaves behind. "It has been a privilege to work with the incredible people at SomnoMed. I am proud of what we have achieved and am comfortable that I am leaving the business in capable hands."
Guy Russo, chair of the board at SomnoMed, publicly thanked Blickstead for her dedication, specifically citing her commitment to organizational change and the development of a top-tier management team that has positioned the company to tackle the current challenges in the sleep medicine market.
Chronology of Development
The release of Virtus is the culmination of a rigorous development cycle:
- Pre-2024: Identification of the clinical need for an appliance that balances airway management with high-impact bruxism protection.
- Early 2024: Finalization of the design for the Virtus, focusing on the reinforced polyamide strap and clear PMMA construction.
- Mid-2024: Successful acquisition of FDA 510(k) clearance, validating the device against the predicate SomnoDent Avant.
- July 2024: Executive leadership transition, with Karen Borg moving to the sole CEO position to oversee the upcoming product launch.
- August 2026 (Current): Initiation of the controlled market release across North America, Europe, and the Asia-Pacific, allowing for real-world data collection and feedback from sleep medicine specialists.
Supporting Data and Clinical Implications
The introduction of the Virtus device comes at a time when the prevalence of sleep-disordered breathing is on the rise globally. According to clinical literature, sleep bruxism is present in approximately 8% to 15% of the adult population, and the frequency of this condition often correlates with sleep apnea.
For clinicians, the primary implication of the Virtus is the reduction of "device failure" instances. In the past, patients with severe bruxism often saw their oral appliances crack or lose their tension settings within months, requiring frequent repairs or replacements. By utilizing the metal-core strap, SomnoMed is providing a product that promises a longer lifespan, effectively lowering the total cost of ownership for the patient and reducing the administrative burden on dental practices.
Furthermore, the "controlled market release" strategy is a prudent approach to gathering post-market clinical data. By rolling out the product in specific regions, SomnoMed can monitor the device’s performance in varied patient demographics, ensuring that the structural integrity of the Virtus holds up to the diverse intensities of bruxism found across different patient populations.
Future Outlook for SomnoMed
As SomnoMed moves forward under the sole leadership of Karen Borg, the company faces a competitive landscape that is increasingly focused on the "connected" nature of sleep therapy. While the Virtus is currently a mechanical solution, the company’s focus on material durability suggests a strategic intent to remain the preferred partner for dentists who require reliable, long-lasting hardware for their patients.
The transition to a single CEO structure suggests that the company is looking to streamline its decision-making processes. With the Virtus now in the market, the focus will likely shift to scaling distribution and ensuring that dental practitioners are properly trained on the nuances of fitting this new, reinforced appliance.
Conclusion
The launch of the Virtus device is more than just a product release; it is a direct response to a specific, unmet need in the sleep medicine community. By acknowledging that OSA patients are often also bruxers, SomnoMed has demonstrated an understanding of the holistic patient experience.
As the medical community continues to shift toward personalized sleep therapies, appliances like the Virtus—which combine the gold-standard science of mandibular advancement with the physical resilience needed for heavy-duty daily use—are likely to become the new benchmark. With a solid executive team now in place and a clear focus on addressing both apnea and the secondary dental effects of sleep-related disorders, SomnoMed appears well-positioned to maintain its trajectory of growth and clinical impact in the global sleep market.
